Seneca Biopharma Inc. [NASDAQ: SNCA] surged by $0.21 during the normal trading session on Wednesday and reaching a high of $2.05 during the day while it closed the day at $1.88. The company report on February 10, 2021 that INVESTIGATION ALERT: Halper Sadeh LLP Investigates GWPH, COHR, FLIR, SNCA; Shareholders Are Encouraged to Contact the Firm.
Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:
GW Pharmaceuticals plc (NASDAQ:GWPH) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Jazz Pharmaceuticals plc for $200.00 in cash and $20.00 in Jazz ordinary shares for each GW American Depositary Share (ADS). If you are a GW Pharmaceuticals shareholder, click here to learn more about your rights and options.
Seneca Biopharma Inc. stock has also gained 27.03% of its value over the past 7 days. However, SNCA stock has inclined by 229.88% in the 3 months of the year. Over the past six months meanwhile, it has gained 155.82% and gained 113.64% year-on date.
The market cap for SNCA stock reached $32.32 million, with 17.31 million shares outstanding and 17.16 million shares in the current float. Compared to the average trading volume of 3.44M shares, SNCA reached a trading volume of 11586436 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Seneca Biopharma Inc. [SNCA]:
The Average True Range (ATR) for Seneca Biopharma Inc. is set at 0.20, with the Price to Sales ratio for SNCA stock in the period of the last 12 months amounting to 2390.33. The Price to Book ratio for the last quarter was 2.29, with the Price to Cash per share for the same quarter was set at 0.74.
SNCA stock trade performance evaluation
Seneca Biopharma Inc. [SNCA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 27.03. With this latest performance, SNCA shares gained by 36.23% in over the last four-week period, additionally plugging by 155.82% over the last 6 months – not to mention a rise of 75.70% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SNCA stock in for the last two-week period is set at 70.89, with the RSI for the last a single of trading hit 73.69, and the three-weeks RSI is set at 69.53 for Seneca Biopharma Inc. [SNCA]. The present Moving Average for the last 50 days of trading for this stock 1.1099, while it was recorded at 1.6380 for the last single week of trading, and 0.8165 for the last 200 days.
Seneca Biopharma Inc. [SNCA]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Seneca Biopharma Inc. [SNCA] shares currently have an operating margin of -56071.81. Seneca Biopharma Inc.’s Net Margin is presently recorded at -54252.64.
Return on Total Capital for SNCA is now -152.01, given the latest momentum, and Return on Invested Capital for the company is -147.50. Return on Equity for this stock declined to -149.46, with Return on Assets sitting at -117.07. When it comes to the capital structure of this company, Seneca Biopharma Inc. [SNCA] has a Total Debt to Total Equity ratio set at 3.53. Additionally, SNCA Total Debt to Total Capital is recorded at 3.41, with Total Debt to Total Assets ending up at 2.75. Long-Term Debt to Equity for the company is recorded at 2.90, with the Long-Term Debt to Total Capital now at 2.80.
Reflecting on the efficiency of the workforce at the company, Seneca Biopharma Inc. [SNCA] managed to generate an average of -$1,670,330 per employee. Receivables Turnover for the company is 0.08 with a Total Asset Turnover recorded at a value of 0.00.Seneca Biopharma Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 15.00 and a Current Ratio set at 15.00.
Earnings per share (EPS) analysis for Seneca Biopharma Inc. [SNCA] stock
With the latest financial reports released by the company, Seneca Biopharma Inc. posted -13/share EPS, while the average EPS was predicted by analysts to be reported at -9.1/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -42.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SNCA.
Seneca Biopharma Inc. [SNCA]: Insider Ownership positions
There are presently around $1 million, or 12.70% of SNCA stock, in the hands of institutional investors. The top three institutional holders of SNCA stocks are: SABBY MANAGEMENT, LLC with ownership of 393,411, which is approximately 242.094% of the company’s market cap and around 0.82% of the total institutional ownership; RENAISSANCE TECHNOLOGIES LLC, holding 167,512 shares of the stock with an approximate value of $0.28 million in SNCA stocks shares; and HIGHTOWER ADVISORS, LLC, currently with $0.17 million in SNCA stock with ownership of nearly -33.354% of the company’s market capitalization.
Positions in Seneca Biopharma Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 6 institutional holders increased their position in Seneca Biopharma Inc. [NASDAQ:SNCA] by around 301,760 shares. Additionally, 10 investors decreased positions by around 184,945 shares, while 7 investors held positions by with 277,999 shares. The mentioned changes placed institutional holdings at 764,704 shares, according to the latest SEC report filing. SNCA stock had 3 new institutional investments in for a total of 21,249 shares, while 5 institutional investors sold positions of 23,989 shares during the same period.